Shanghai's "4+7" varieties were collected from Qilu, Jingxin and other enterprises to win the bid

On July 12, the Shanghai Sunshine Pharmaceutical Purchasing Network issued an announcement, announcing the results of the Shanghai Centralized Pharmaceutical Purchasing (SH-DL2021-1) selection

Different from the previous national sourcing, this Shanghai centralized sourcing was conducted separately for 9 varieties

The specific replacement content of the winning bidder is as follows:

The bidding company for atorvastatin calcium tablets was changed from Lepu Pharmaceuticals to Qilu Pharmaceuticals

The winning company for Entecavir tablets was changed from Guangshengtang to Qilu Pharmaceutical

The winning bidder of Olanzapine Tablets was changed from Hausen Pharmaceuticals to Qilu Pharmaceuticals

The winning bidder of cefuroxime axetil tablets was changed from Chengdu Better to Jingxin Pharmaceutical

The winning bidder of Tenofovir Disoproxil fumarate tablets was changed from Chengdu Beite to Qilu Pharmaceutical

Judging from the results of winning bids, with the advancement of the consistency evaluation work, large generic drug manufacturers still have strong strengths.

According to the Shanghai centralized procurement documents, the criteria for determining the drug to be selected is that the "comparable unit price" of the final drug meets one of the following conditions, and the comprehensive score is calculated according to the "comprehensive bidding index system", and the company with the highest score is proposed to be selected:

(1) "Comparable unit price" ≤ 1.

(2) "Comparable price per unit" ≤ average price of the same species selected in national centralized procurement

The policies for renewal of centralized procurement varieties are different in different regions.